PJ34, the inhibitor of Poly [ADP-ribose] polymerase 1 (PARP-1), which is involved in the regulation of cell differentiation and proliferation, recovery from DNA damage, induction of inflammation, and pathophysiology of type I diabetes [61], was recently proposed as a potential drug against cancer [62], endothelial dysfunction and hypertension [63]. Here, PARP1 is linked to endothelial dysfunction.